The Cigna Group

Valuation Analysis

About the Company

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. It operates through two segments: Evernorth Health Services and Cigna Healthcare. The Evernorth Health Services segment includes Pharmacy Benefit Services and Specialty and Care Services, offering pharmacy benefit management, drug claim adjudication, retail pharmacy network administration, benefit design consultation, drug utilization review, drug formulary management, pharmacy benefits, home delivery pharmacy, specialty pharmacy, specialty pharmaceutical distribution, and clinical programs for whole-person health outcomes. The Cigna Healthcare segment comprises U.S. Healthcare and International Health, delivering comprehensive medical and coordinated solutions such a

The Cigna Group Stock at a Glance

The Cigna Group (CI) is currently trading at $298.00 with a market capitalization of $78.8B. The trailing P/E ratio stands at 11.92x, with a forward P/E of 8.9x. The 52-week range spans from $239.51 to $338.89; the current price is 12.1% below the yearly high. Year-over-year revenue growth stands at +4.6%. The net profit margin stands at 2.26%.

💰 Dividend

The Cigna Group pays an annual dividend of $6.24 per share, representing a yield of 2.09%. The payout ratio stands at 24.36%.

📊 Analyst Rating

24 analysts rate The Cigna Group (CI) on consensus: Buy. The average price target is $340.92, implying +14.4% from the current price. Analyst price targets range from $290.00 to $400.00.

The Cigna Group: The Investment Case in Detail

The Cigna Group (CI) operates in the Healthcare — specifically Healthcare Plans — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

Earnings growth of 29.1% is outpacing revenue, a sign of operational leverage — fixed costs are being absorbed across a larger base. Our valuation screen flags the stock as undervalued relative to its fundamentals — multiples are running below where the cash flow profile would normally justify.

The Bear Case

Revenue growth has slowed to just 4.6%, which is below nominal GDP — the business is no longer outgrowing the broader economy. With a net margin of just 2.26%, the business has little room to absorb cost shocks or pricing pressure — a single bad quarter can swing the company to a loss.

Valuation in Context

With a PEG ratio of 0.89, the price-to-earnings multiple is actually below the company's growth rate — classic value-meets-growth territory that Peter Lynch would have called a 'GARP' opportunity. The EV/EBITDA multiple of 7.63x is below the historical equity-market average — strategic acquirers would find the cash-flow profile attractive at this level.

What to Watch Next

• The forward P/E of 8.9x is meaningfully below the trailing 11.92x — analysts expect earnings to step up; the next earnings release is the test.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Risk Profile

The data points to relatively defensive market behavior.

Trading Data

💵 Dividend Info

Related Stocks in the Same Sector

Where can I buy The Cigna Group?

Compare top-rated brokers — low fees, trusted providers, fully regulated.